Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.

Yang W, Schwartz GN, Marotti JD, Chen V, Traphagen NA, Gui J, Miller TW.

Oncotarget. 2018 Jan 15;9(10):8810-8822. doi: 10.18632/oncotarget.24256. eCollection 2018 Feb 6.

2.

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.

Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P.

Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31.

3.

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.

Tafe LJ, Gorlov IP, de Abreu FB, Lefferts JA, Liu X, Pettus JR, Marotti JD, Bloch KJ, Memoli VA, Suriawinata AA, Dragnev KH, Fadul CE, Schwartz GN, Morgan CR, Holderness BM, Peterson JD, Tsongalis GJ, Miller TW, Chamberlin MD.

Oncologist. 2015 Sep;20(9):1011-8. doi: 10.1634/theoncologist.2015-0097. Epub 2015 Jul 23.

4.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.

Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.

5.

Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer.

MacKenzie TA, Schwartz GN, Calderone HM, Graveel CR, Winn ME, Hostetter G, Wells WA, Sempere LF.

Am J Pathol. 2014 Dec;184(12):3217-25. doi: 10.1016/j.ajpath.2014.08.020. Epub 2014 Nov 6.

6.

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking.

Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, Moore JH, Saykin AJ.

Psychooncology. 2014 Dec;23(12):1382-90. doi: 10.1002/pon.3545. Epub 2014 Apr 30.

7.

Personalized therapy for breast cancer.

De Abreu FB, Schwartz GN, Wells WA, Tsongalis GJ.

Clin Genet. 2014 Jul;86(1):62-7. doi: 10.1111/cge.12381. Epub 2014 Apr 9. Review.

PMID:
24635704
8.

Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience.

Meaney PM, Kaufman PA, Muffly LS, Click M, Poplack SP, Wells WA, Schwartz GN, di Florio-Alexander RM, Tosteson TD, Li Z, Geimer SD, Fanning MW, Zhou T, Epstein NR, Paulsen KD.

Breast Cancer Res. 2013 Apr 24;15(2):R35. doi: 10.1186/bcr3418.

9.

A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue.

McGowan MM, Eisenberg BL, Lewis LD, Froehlich HM, Wells WA, Eastman A, Kuemmerle NB, Rosenkrantz KM, Barth RJ Jr, Schwartz GN, Li Z, Tosteson TD, Beaulieu BB Jr, Kinlaw WB.

Breast Cancer Res Treat. 2013 Feb;138(1):175-83. doi: 10.1007/s10549-013-2446-9. Epub 2013 Feb 16.

10.

ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.

Balboni AL, Hutchinson JA, DeCastro AJ, Cherukuri P, Liby K, Sporn MB, Schwartz GN, Wells WA, Sempere LF, Yu PB, DiRenzo J.

Cancer Res. 2013 Jan 15;73(2):1020-30. doi: 10.1158/0008-5472.CAN-12-2862. Epub 2012 Dec 14.

11.

Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve.

Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA.

J Clin Oncol. 2010 Oct 10;28(29):4434-40. doi: 10.1200/JCO.2009.27.0827. Epub 2010 Sep 13.

12.

Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changes.

Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA, Forero JA, Muffly LS, Schwartz GN, Paulsen KD, Kaufman PA.

Radiology. 2009 Aug;252(2):551-60. doi: 10.1148/radiol.2522081202. Epub 2009 Jun 9.

13.

Cognitive function in breast cancer patients prior to adjuvant treatment.

Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA.

Breast Cancer Res Treat. 2008 Jul;110(1):143-52. Epub 2007 Aug 3.

14.

Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker.

Wells WA, Schwartz GN, Morganelli PM, Cole BF, Gibson JJ, Kinlaw WB.

Breast Cancer Res Treat. 2006 Jul;98(2):231-40. Epub 2006 Mar 22.

PMID:
16552628
15.

The functions of plasminogen activator inhibitor-1: do we have all the pieces of PAI?

Mulligan-Kehoe MJ, Schwartz GN, Zacharski LR.

Thromb Res. 2006;117(5):483-6. Epub 2005 Jul 1. No abstract available.

PMID:
15993475
16.

Proliferation kinetics of subpopulations of human marrow cells determined by quantifying in vivo incorporation of [2H2]-glucose into DNA of S-phase cells.

Schwartz GN, Vance BA, Levine BM, Fukazawa M, Telford WG, Cesar D, Hellerstein M, Gress RE.

Blood. 2003 Sep 15;102(6):2068-73. Epub 2003 May 22.

17.

Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.

Ramnath N, Schwartz GN, Smith P, Bong D, Kanter P, Berdzik J, Creaven PJ.

Cancer Chemother Pharmacol. 2003 Mar;51(3):227-30. Epub 2003 Feb 25.

PMID:
12655441
18.

Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? Multiple gated acquisition.

Sabel MS, Levine EG, Hurd T, Schwartz GN, Zielinski R, Hohn D, Edge SB.

Am J Clin Oncol. 2001 Aug;24(4):425-8.

PMID:
11474280
19.

Thrombopoietin and chemokine mRNA expression in patient post-chemotherapy and in vitro cytokine-treated marrow stromal cell layers.

Schwartz GN, Kammula U, Warren MK, Park MK, Yan XY, Marincola FM, Gress RE.

Stem Cells. 2000;18(5):331-42.

20.

Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond-Blackfan anaemia.

Giri N, Kang E, Tisdale JF, Follman D, Rivera M, Schwartz GN, Kim S, Young NS, Rick ME, Dunbar CE.

Br J Haematol. 2000 Jan;108(1):167-75.

PMID:
10651740
21.
22.

Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways.

Koski GK, Schwartz GN, Weng DE, Czerniecki BJ, Carter C, Gress RE, Cohen PA.

J Immunol. 1999 Jul 1;163(1):82-92.

23.

The clinical development of paclitaxel and the paclitaxel/carboplatin combination.

Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D, Creaven P.

Eur J Cancer. 1998 Sep;34(10):1543-8. Review.

PMID:
9893625
24.

Growth inhibition of chronic myelogenous leukemia cells by ODN-1, an aptameric inhibitor of p210bcr-abl tyrosine kinase activity.

Schwartz GN, Liu YQ, Tisdale J, Walshe K, Fowler D, Gress R, Bergan RC.

Antisense Nucleic Acid Drug Dev. 1998 Aug;8(4):329-39.

PMID:
9743470
25.

Post-chemotherapy and cytokine pretreated marrow stromal cell layers suppress hematopoiesis from normal donor CD34+ cells.

Schwartz GN, Warren MK, Rothwell SW, Zujewski J, Halverson DC, Cowan KH, Tolcher A, O'Shaughnessy J, Gress RE.

Bone Marrow Transplant. 1998 Sep;22(5):457-68.

26.

In vitro generation of allospecific human CD8+ T cells of Tc1 and Tc2 phenotype.

Halverson DC, Schwartz GN, Carter C, Gress RE, Fowler DH.

Blood. 1997 Sep 1;90(5):2089-96.

28.

Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging.

Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L.

Blood. 1996 Jul 15;88(2):731-41.

29.

Comparative effects of insulin-like growth factor II (IGF-II) and IGF-II mutants specific for IGF-II/CIM6-P or IGF-I receptors on in vitro hematopoiesis.

Schwartz GN, Warren MK, Sakano K, Szabo JM, Kessler SW, Pashapour A, Gress RE, Perdue JF.

Stem Cells. 1996 May;14(3):337-50.

30.

Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging.

Seth P, Brinkmann U, Schwartz GN, Katayose D, Gress R, Pastan Ira, Cowan K.

Cancer Res. 1996 Mar 15;56(6):1346-51.

31.

Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow.

Schwartz GN, Hakim F, Zujewski J, Szabo JM, Cepada R, Riseberg D, Warren MK, Mackall CL, Setzer A, Noone M, Cowan KH, O'Shaughnessy J, Gress RE.

Br J Haematol. 1996 Mar;92(3):537-47.

PMID:
8616014
32.

Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.

Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, Demetri GD, Anderson KC.

Transfusion. 1996 Feb;36(2):160-7.

PMID:
8614968
33.

Early suppressive effects of chemotherapy on recovery of bone marrow megakaryocyte precursors: possible relationship to platelet recovery.

Warren MK, Zujewski J, Rose WL, Szabo JM, O'Shaughnessy JA, Halverson DC, Cowan KH, Gress RE, Schwartz GN.

Stem Cells. 1996;14 Suppl 1:31-7.

34.
35.

Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia.

Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufmann SH.

Blood. 1995 Jan 1;85(1):186-93.

36.

Inhibitory effects of HIV-1-infected stromal cell layers on the production of myeloid progenitor cells in human long-term bone marrow cultures.

Schwartz GN, Kessler SW, Rothwell SW, Burrell LM, Reid TJ, Meltzer MS, Wright DG.

Exp Hematol. 1994 Dec;22(13):1288-96. Erratum in: Exp Hematol 1995 Feb;23(2):181.

PMID:
7525330
37.

Oxygenation of human tumor xenografts in nude mice by a perfluorochemical emulsion and carbogen breathing.

Teicher BA, Schwartz GN, Dupuis NP, Kusomoto T, Liu M, Liu F, Northey D.

Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1369-75.

PMID:
7849946
39.

Oxygenation of tumors by a hemoglobin solution.

Teicher BA, Schwartz GN, Alvarez Sotomayor E, Robinson MF, Dupuis NP, Menon K.

J Cancer Res Clin Oncol. 1993;120(1-2):85-90.

PMID:
8270614
40.

Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Schwartz GN, Teicher BA, Eder JP Jr, Korbut T, Holden SA, Ara G, Herman TS.

Cancer Chemother Pharmacol. 1993;32(6):455-62.

PMID:
8258194
41.

Minocycline in combination with chemotherapy or radiation therapy in vitro and in vivo.

Sotomayor EA, Teicher BA, Schwartz GN, Holden SA, Menon K, Herman TS, Frei E 3rd.

Cancer Chemother Pharmacol. 1992;30(5):377-84.

PMID:
1505076
42.
43.
45.

Radioprotection of mice with interleukin-1: relationship to the number of spleen colony-forming units.

Schwartz GN, Patchen ML, Neta R, MacVittie TJ.

Radiat Res. 1989 Jul;119(1):101-12.

PMID:
2787916
46.

Removal of peripheral blood monocytes by phenylalanine methyl ester has no effect on the colony growth of hematopoietic progenitor cells.

Law P, Schwartz GN, Alsop T, Haiber LM, Smith DM, Dooley DC.

Int J Cell Cloning. 1989 Mar;7(2):100-10.

PMID:
2723463
47.

Recovery of hematopoietic colony-forming cells in irradiated mice pretreated with interleukin 1 (IL-1).

Schwartz GN, Neta R, Vigneulle RM, Patchen ML, MacVittie TJ.

Exp Hematol. 1988 Oct;16(9):752-7.

PMID:
3262530
48.

Enhanced hematopoietic recovery in irradiated mice pretreated with interleukin-1 (IL-1).

Schwartz GN, MacVittie TJ, Vigneulle RM, Patchen ML, Douches SD, Oppenheim JJ, Neta R.

Immunopharmacol Immunotoxicol. 1987;9(2-3):371-89.

PMID:
3325546
50.

Countercurrent centrifugal elutriation (CCE) recovery profiles of hematopoietic stem cells in marrow from normal and 5-FU-treated mice.

Schwartz GN, MacVittie TJ, Monroy RL, Vigneulle RM.

Exp Hematol. 1986 Nov;14(10):963-70.

PMID:
3770103

Supplemental Content

Loading ...
Support Center